June 18, 2008 – Suven Life Sciences Ltd, a Drug Discovery and development company announced at Bio-2008, San Diego that they commenced Phase I clinical trials of SUVN-502, a potent, safe, highly selective, brain penetrant and orally active antagonist at a nonperipheral, CNS receptor site 5-HT6, intended for the symptomatic treatment of Alzheimer’s disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson, Schizophrenia. The study is being conducted at Basel, Switzerland under a Clinical Trial Application (CTA) approved by SwissMedic, the regulatory authority of Switzerland. The study is expected to be completed by Dec 2008.
SUVN-502 is the lead compound, selected from a series of more than 500 compounds, which were innovatively designed and developed using the combination of traditional and rational medicinal chemistry approaches... Suven Life Sciences' Press Release -
